CAR-Expressing Natural Killer Cells for Cancer Retargeting

Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltr...

Full description

Saved in:
Bibliographic Details
Published inTransfusion medicine and hemotherapy Vol. 46; no. 1; pp. 4 - 13
Main Authors Kloess, Stephan, Kretschmer, Anna, Stahl, Lilly, Fricke, Stephan, Koehl, Ulrike
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.02.2019
Subjects
Review
Review Article
Natural killer cells
Chimeric antigen receptor
NK-92
Haematological malignancies
Solid tumour
CAR-NK cell
Online AccessGet full text

Cover

More Information
Summary:Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an “off the shelf product” and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
S.K. and A.K. contributed equally to this work; S.F. and U.K. shared authorship.
ISSN:1660-3796
1660-3818
DOI:10.1159/000495771